BRPI0520209A2 - agente para a prevenÇço e tratamento de doenÇas do fÍgado contendo derivado de pirazolopirimidina - Google Patents

agente para a prevenÇço e tratamento de doenÇas do fÍgado contendo derivado de pirazolopirimidina

Info

Publication number
BRPI0520209A2
BRPI0520209A2 BRPI0520209-4A BRPI0520209A BRPI0520209A2 BR PI0520209 A2 BRPI0520209 A2 BR PI0520209A2 BR PI0520209 A BRPI0520209 A BR PI0520209A BR PI0520209 A2 BRPI0520209 A2 BR PI0520209A2
Authority
BR
Brazil
Prior art keywords
pyrazolopyrimidine derivative
prevention
treatment
liver diseases
present
Prior art date
Application number
BRPI0520209-4A
Other languages
English (en)
Inventor
Seul Min Choi
Byoung Ok Ahn
Moohi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of BRPI0520209A2 publication Critical patent/BRPI0520209A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

AGENTE PARA A PREVENÇçO E TRATAMENTO DE DOENÇAS DO FÍGADO CONTENDO DERIVADO DE PIRAZOLOPIRIMIDINA. A presente invenção se refere a uma composição farmacêutica para prevenção e tratamento de doenças do figado, contendo derivado de pirazolopirimidina como ingrediente ativo. De acordo com a presente invenção, o derivado de pirazolopirimidina tem um efeito excelente sobre a inibição da síntese de colágeno nas células estreladas hepáticas, e age diretamente sobre a veia porta. Especificamente, ele pode aumentar o diâmetro e a quantidade do fluxo de sangue da veia porta, e, por fim, diminuir a pressão dela. Portanto, o derivado de pirazolopirimidina pode ser usado de maneira eficaz na prevenção e no tratamento de fibrose hepática, cirrose hepática provocada por fibrose hepática, hipertensão portal e de diversas complicações causadas por hipertensão portal. Além disso, o derivado de pirazolopirimidina de acordo com a presente invenção pode reduzir a freqúência de dosagem graças a sua longa meia-vida, e, portanto, tem a vantagem de melhorar a adesão ao tratamento com remédios dos pacientes que sofrem de doenças crônicas do figado.
BRPI0520209-4A 2005-06-10 2005-10-21 agente para a prevenÇço e tratamento de doenÇas do fÍgado contendo derivado de pirazolopirimidina BRPI0520209A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050050033 2005-06-10
PCT/KR2005/003526 WO2006132460A1 (en) 2005-06-10 2005-10-21 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Publications (1)

Publication Number Publication Date
BRPI0520209A2 true BRPI0520209A2 (pt) 2009-04-22

Family

ID=37498629

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520209-4A BRPI0520209A2 (pt) 2005-06-10 2005-10-21 agente para a prevenÇço e tratamento de doenÇas do fÍgado contendo derivado de pirazolopirimidina

Country Status (22)

Country Link
US (1) US8796286B2 (pt)
EP (1) EP1888074B1 (pt)
JP (1) JP4879977B2 (pt)
KR (1) KR100914445B1 (pt)
CN (1) CN101193636B (pt)
AT (1) ATE537832T1 (pt)
AU (1) AU2005332719B2 (pt)
BR (1) BRPI0520209A2 (pt)
CA (1) CA2611638C (pt)
CY (1) CY1112637T1 (pt)
DK (1) DK1888074T3 (pt)
ES (1) ES2376628T3 (pt)
HK (1) HK1119596A1 (pt)
IL (1) IL187678A (pt)
MX (1) MX2007015365A (pt)
NO (1) NO20076053L (pt)
NZ (1) NZ564369A (pt)
PT (1) PT1888074E (pt)
RU (1) RU2369392C2 (pt)
UA (1) UA86528C2 (pt)
WO (1) WO2006132460A1 (pt)
ZA (1) ZA200800180B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101809B1 (en) * 2006-12-28 2011-10-19 Insect Biotech Co., Ltd. Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP6235583B2 (ja) * 2012-07-11 2017-11-22 ユニバーシティー オブ ミシシッピ メディカル センター 画像獲得データから肝線維症を検出及びステージ決定する方法
AU2015258805B2 (en) 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
JP7033454B2 (ja) 2015-06-30 2022-03-10 カンバーランド ファーマシューティカルズ，インコーポレーテッド Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬
ES2955158T3 (es) 2016-05-11 2023-11-29 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
AU2022325803A1 (en) * 2021-08-13 2024-03-28 Goldberg, David J. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100377782B1 (ko) 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
AU2003286555A1 (en) 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja) 2003-05-15 2004-12-16 Kumiai Chemical Industry Co., Ltd. フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2528975A1 (en) * 2003-06-10 2004-12-16 Pfizer Inc. Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren

Also Published As

Publication number Publication date
CA2611638C (en) 2010-08-24
WO2006132460A1 (en) 2006-12-14
JP2008543748A (ja) 2008-12-04
CA2611638A1 (en) 2006-12-14
PT1888074E (pt) 2012-03-01
CN101193636A (zh) 2008-06-04
US8796286B2 (en) 2014-08-05
RU2007149474A (ru) 2009-07-20
US20080207646A1 (en) 2008-08-28
UA86528C2 (uk) 2009-04-27
EP1888074B1 (en) 2011-12-21
KR20060128605A (ko) 2006-12-14
EP1888074A4 (en) 2010-06-23
KR100914445B1 (ko) 2009-08-28
MX2007015365A (es) 2008-02-12
DK1888074T3 (da) 2012-01-23
NO20076053L (no) 2008-02-27
JP4879977B2 (ja) 2012-02-22
RU2369392C2 (ru) 2009-10-10
HK1119596A1 (en) 2009-03-13
ZA200800180B (en) 2009-01-28
CY1112637T1 (el) 2016-02-10
AU2005332719B2 (en) 2010-05-13
CN101193636B (zh) 2011-12-28
ATE537832T1 (de) 2012-01-15
EP1888074A1 (en) 2008-02-20
AU2005332719A1 (en) 2006-12-14
IL187678A (en) 2013-04-30
NZ564369A (en) 2010-03-26
IL187678A0 (en) 2008-11-03
ES2376628T3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0520209A2 (pt) agente para a prevenÇço e tratamento de doenÇas do fÍgado contendo derivado de pirazolopirimidina
NO20075136L (no) Nye liposompreparater
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MX2009011900A (es) Curacion de herida diabetica.
WO2005035485A3 (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
FR2850023B1 (fr) Medicaments pour le systeme nerveux
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
MY148300A (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
SE0000303D0 (sv) Novel compounds
SE0303135D0 (sv) Controlled food effect composition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]